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Testosterone production through the HPG axis is a tightly controlled, 
multi-phased biochemical process. Initially, gonadotropin-releasing 
hormone (GNRH) is secreted from the hypothalamus in a circadian, 
pulsatile fashion into the portal vascular system. This system 
provides connection to the anterior pituitary, where GNRH is 
rapidly internalized, triggering systemic release of follicle stimulating 
hormone (FSH) and luteinizing hormone (LH). FSH targets sertoli 
cells and spermatogonial membranes that regulate the process of 
spermatogenesis, whereas LH targets Leydig cells whose role is to 
produce testosterone.11
Once produced, testosterone is released into the systemic 
circulation where it is either protein bound or unbound. Approximately 
30% is tightly protein bound by sex hormone binding globulin (SHBG) 
and physiologically inactive.12,13 SHBG is produced in the liver 
and circulating levels can be influenced by disease states such 
as hyperthyroidism, cirrhosis, and HIV, which increase SHBG, 
whereas hypothyroidism, obesity, and nephrotic syndrome decrease 
SHBG.14,15 Approximately, 68% of serum testosterone is loosely 
protein bound by albumin and can be coupled with unbound, free 
testosterone to deter mine bioavailable testosterone.14 Physiologically 
active, unbound testosterone that is free to exert cytologic effects 
comprises approximately 2% of circulating testosterone.12,14,15 Within 
non-testicular tissue, testosterone can be converted to the more potent 
dihydrotestosterone via the 5α-reductase enzyme or to other androgens 
such as estrogen via the aromatase enzyme. Intratesticular testosterone 
levels (200–1000 ng ml−1) are 80–100 fold higher than serum levels and 
are critical for spermatogenesis and maintained by androgen binding 
protein produced by sertoli cells.16 In addition to testosterone, estrogen 
INTRODUCTION
Testosterone has now become one of the most widely used medications 
in the United States. This is partly due to an increasing proportion 
of the population > 65 years of age and the increasing incidence of 
medical co-morbidities associated with low testosterone, such as 
diabetes, metabolic syndrome, and cardiovascular disease.1,2 It is 
well documented that the incidence of testosterone deficiency (TD) 
increases with age, partly due to a 0.4%–2.0% per year decline in 
testosterone production after age 30.3,4 The incidence of TD in healthy, 
middle-aged men has been reported as high as 6%, with greater 
increases associated with age beyond 60, medical co-morbidities, and 
poor health status.5–7 In fact, males in the seventh decade have mean 
plasma testosterone levels 35% lower than young men.8 Given the 
nonspecific symptoms and variation in testosterone levels associated 
with the presentation of this disease, diagnosis and treatment still 
remain a challenge despite an increasing incidence.9 This is evidenced 
by the fact that only 12% of clinically symptomatic, hypogonadal males 
are successfully treated despite access to care.10 Therefore, as the usage 
of testosterone supplementation therapy (TST) continues to increase, 
clinicians will be challenged to maintain an up-to-date understanding 
of the diagnosis and management of TD.
PHYSIOLOGY
Testosterone plays a critical role in modulating male sexual 
development, adult male reproductive health, and sexual function. 
In addition, it is critical in maintaining lean muscle mass, bone 
mineral density, and fat metabolism.11 Testosterone production 
is regulated by the hypothalamic-pituitary-gonadal  (HPG) axis. 
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aromatized from testosterone, other androgens, and inhibin all provide 
negative feedback inhibition at the level of the hypothalamus and 
pituitary glands modulating production.17
Serum testosterone levels can vary over time due to a variety 
of factors. Diurnal variation, based upon circadian rhythm-driven, 
pulsatile hypothalamic release of GNRH, results in peak serum 
testosterone levels during the morning hours. Blunting of the diurnal 
peak has been shown to occur with aging,18 however a significant 
proportion of older men aged 65–80 with low afternoon serum 
testosterone levels will have normal levels in the morning.19,20 
Furthermore, 15% of young, healthy men can demonstrate abnormally 
low levels within a 24 h period.19 Some of this variation can be explained 
by assay variation, but a certain amount is due to biologic variation 
from glucose ingestion, triglyceride levels, diurnal, seasonal variation, 
and activities performed prior to lab draw.21,22
ETIOLOGY
Classification
TD can be caused by a failure of the testes to produce testosterone, 
interruption of one or several layers of the HPG axis, androgen 
target tissue dysfunction, or environmental factors such as 
medications or chronic medical illness. TD can be classified as 
secondary  (or hypogonadotropic) hypogonadism when disruption 
of the HPG axis leads to inadequate FSH and LH production.15,17,23,24 
One important cause of secondary hypogonadism is pituitary 
dysfunction from hypopituitarism related to radiation, infection, 
trauma, hyperprolactinemia from hormone-secreting pituitary 
adenomas, dopaminergic medications, or medical conditions such as 
chronic renal failure and hypothyroidism.25 Other causes of secondary 
hypogonadism are primary GNRH deficiency from Kallmann 
syndrome, Prader–Willi syndrome, and idiopathic hypogonadotropic 
hypogonadism. Secondary hypogonadism may also result from GNRH 
deficiency from medications, radiation, chronic illness or conditions 
resulting in elevated serum levels of inhibin.25,26
Primary (or hypergonadotropic) hypogonadism refers to testicular 
failure in production of testosterone and spermatogenesis in presence 
of elevated gonadotropins.15,17,23,24 Common intratesticular causes 
include a history of treatment for testicular tumor, prior infection 
such as orchitis, chemotherapy, medications with gonadotoxic effects, 
environmental toxins, idiopathic testicular atrophy, or iatrogenic 
removal for trauma or malignancy.17,23,24 One of the more common 
intratesticular genetic causes of primary hypogonadism includes 
Klinefelter’s syndrome, affecting 0.2% of the male population and 
representing the most common numerical chromosomal aberration.27 
Klinefelter’s is often diagnosed during a male factor infertility evaluation 
for severe oligospermia or azoospermia, which can reveal other causes 
of male factor infertility associated with primary hypogonadism. Some 
such causes are genetic, including Y-chromosome microdeletions, 
chromosomal aberration, 47  XYY syndrome, gonadal dysgenesis, 
or 46 XY disorders of sexual development.25 Other such causes are 
anatomic as with varicoceles.28 Varicoceles cause intratesticular 
dysfunction secondary to testicular hyperthermia, reflux of venous 
toxins, and increased reactive oxygen species due to relative hypoxia. 
Finally, hypogonadism related to defects in androgen target tissue 
utilization of testosterone such as androgen insensitivity syndrome, 
which may be partial or complete, and 5α-reductase deficiency are 
rare.24,29
Mixed gonadal dysfunction, often referred to as late onset 
hypogonadism  (LOH), but also known as androgen deficiency 
in the aging male, partial androgen deficiency of the aging male, 
age-associated TD syndrome, male menopause and andropause; 
has become an increasingly important entity.3,17,24,30 The age-related 
symptomatic decrease in serum testosterone has been shown to 
occur in approximately 3% and 5% of men in the sixth and seventh 
decades, respectively.7 Several physiologic changes can account for 
this phenomenon. SHBG levels have been shown to increase with age, 
reducing bioavailable and free serum testosterone levels.14,15 LH may be 
variably elevated in response to a decrease in the number and function 
of the Leydig cell population, which also correlates with the age-related 
decline in spermatogenesis and fertility.8 Some have proposed using 
LH levels in aging men to distinguish compensated hypogonadism 
from pure primary hypogonadism to understand disease severity and 
guide treatment decisions.32 Age-related impairments in the HPG axis 
are also partly responsible, including reduced LH pulse amplitude, LH 
pulse frequency and GNRH production.8 Additionally, the gradual 
increase in co-morbid medical conditions with age can effect the HPG 
axis centrally resulting in HPG axis feedback impairment.
Medications
Several medications have been associated with TD due to induction 
of primary hypogonadism, secondary hypogonadism, or both.17 
Glucocorticoids are well-known for their multi-system side-effects such 
as osteoporosis, but they can also induce mixed primary and secondary 
hypogonadism and decrease SHBG levels.23,33 This process has been 
found to affect up to 80% of men on long-term glucocorticoid therapy 
on cross-sectional analysis.34 Such an effect has been shown to occur 
regardless of dose and can persist for up to 12 months.35,36 Previous 
exposure to exogenous testosterone or anabolic steroids, at any point 
in life, has been shown to negatively impact the HPG axis and may 
cause secondary hypogonadism and infertility, an effect which can 
endure for up to 2 years and in some cases may be permanent.17,37–39 
This effect is more common in younger men as evidenced by the recent 
observation that hypogonadal men < 50 years of age have a 10-fold 
higher risk of previous anabolic steroid exposure than men older than 
50 years of age.40
In addition, GNRH analogs, such as those used for prostate cancer 
treatment, are potent inhibitors of the HPG axis with effects lasting 
up to 3–4  months after cessation of therapy.41 Similarly, isolated 
reports have shown androgen analogs such as megastrol acetate 
used for appetite stimulation in cachectic cancer patients can also 
induce symptomatic male hypogonadism.42 Commonly used opioid 
analgesics have been shown to have suppressive effects on the release of 
gonadotropins centrally and on production of testosterone peripherally 
by Leydig cells.43–45 The onset of action is quick,46 with duration and 
severity of opioid effect on the HPG axis appearing to be related to 
half-life and dose of a particular agent used.47,48 The duration of effect, 
however, appears to be short regardless of duration of therapy.49 Some 
studies with selective serotonin reuptake inhibitors have only shown 
a statistically significant decrease in serum testosterone levels using 
paroxetine,50 whereas other studies using fluoxetine have not.51 Finally, 
statins have also shown a modest but statistically significant decrease 
in serum testosterone levels.52
Medical Conditions
A number of medical conditions have been associated with low serum 
testosterone levels.44 Obesity is strongly associated with hypogonadism, 
with a reported 52% prevalence on large population cross-sectional 
analysis when controlling for obesity-related declines in SHBG.53 
Proposed mechanisms include decreased amplitude of LH pulsatility,54 
increased plasma leptin levels having central and peripheral inhibitory 
effects,55 and peripheral conversion of testosterone to estrogen via 
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adipose tissue-dense aromatase enzyme.56 Often co-morbid with 
obesity, obstructive sleep apnea has been shown to produce a reversible 
dysfunction of the HPG axis independent of the effects of obesity.57,58 
Type 2 diabetes mellitus has also been shown to be highly prevalent in 
hypogonadal males independent of obesity, with rates nearing 50%.53 
Proposed mechanisms include aforementioned obesity-mediated 
pathways with addition of increased insulin resistance at the 
hypothalamic level.59 In sum, the exact relationship between obesity, 
insulin resistance, metabolic syndrome, diabetes, and TD has yet to be 
fully elucidated.57 Available data promote a spectrum of possibilities 
ranging from low testosterone and SHBG levels being predictive of 
development of metabolic syndrome60 to metabolic syndrome being 
a risk factor for development of TD.61
Other chronic medical conditions such as hypertension, 
hyperlipidemia, chronic obstructive pulmonary disease, rheumatoid 
arthritis, chronic kidney disease and erectile dysfunction  (ED) 
have all been linked to TD with high prevalence rates.44,53,62 In most 
cases, the underlying pathways are multifactorial.17 Alcohol abuse 
has been shown to effect the HPG axis at all levels resulting in TD.63 
Acute critical illness has long been known to cause decreases in 
bioavailable testosterone levels.64 HIV is associated with TD in up to 
50% during the preantiretroviral era compared with 20%–25% in the 
postantiretroviral era.44,65,66 The exact mechanism is unknown, but 
early recognition is important, as hypogonadism is strongly associated 
with AIDS wasting syndrome.67,68 Adequate treatment with TST 
demonstrates mitigation of this risk with improvement in several quality 
of life parameters.69 Although rare, hemochromatosis can result in TD 
by causing primary or secondary hypogonadism or both, which is 
potentially reversible with treatment of the underlying etiology.70 Finally, 
men with low testosterone have been found to suffer from some form of 
depression in up to 90% of cases with 17% having severe depression.71
Still somewhat controversial, there is recent evidence that TD may 
be associated with Peyronie’s disease (PD), and TST may improve its 
symptoms. A causative role is unclear, although a complex relationship 
likely exists. TD does lead to the down-regulation of vascular 
endothelial growth factor and up-regulation of transforming growth 
factor beta, resulting in corporal fibrosis.72 Reversal of these findings 
has been shown with TST in animal models.73 While two studies have 
shown a significant association between TD and PD,74,75 a large, recent 
retrospective study found that men presenting with either PD or ED 
have a similar incidence of TD, suggesting TD has a closer relationship 
with the ED component of PD.76
DIAGNOSIS 
Introduction
Despite the recent surge in usage, the diagnosis of TD remains a challenge. 
This is partly due to the diagnosis being dependent upon establishing 
presence of clinical symptoms and low serum testosterone levels.23,24,30 
However, achieving these two criteria remains difficult due to a lack of 
standardization regarding the overall evaluation and management of 
TD.77 This lack of standardization is due to several factors including wide 
variation in presenting symptoms, limited clinical correlation between 
serum androgen levels and symptoms, and various issues with laboratory 
processing and quantification of serum testosterone levels.77
Several specialty societies and expert groups have attempted to 
standardize the diagnostic process, including the United States Endocrine 
Society, European Association of Urology, International Consultation on 
Sexual Medicine (ICSM), and joint guidelines representing numerous 
international andrology societies (Table 1).23,24,30,77,78 Broadly speaking, 
these guidelines emphasize the importance of diagnosis in men who 
first demonstrate clinical signs or symptoms of TD, followed by 
documentation of a low serum testosterone level only in individuals 
who do not exhibit easily reversible causes of TD such as medications 
or acute illness as previously discussed. These guidelines provide a good 
framework within which clinicians can practice. However, they are 
partly based upon generally low quality data, especially when defining 
a low serum testosterone level, and there is some individual expert 
deviation from these in actual clinical practice.77
Clinical Diagnosis
The clinical presentation of TD in adult males can be variable, 
insidious, and often confused with other clinical conditions.78 Because 
testosterone is a key regulator in male sexual function pathways, 
common symptoms of TD include decreased libido, reduced nocturnal 
erections, ED, and male factor infertility.79–82 Additional signs and 
symptoms less specific to TD are reflective of testosterone’s broad 
systemic effects and include decreased energy, decreased cognition, 
reduced muscle mass, reduced strength, increased adiposity, decreased 
bone mineral density, hot flashes, sleep disturbance, and depressed 





Serum total testosterone 
(ng dl−1)




Endocrine society23 Yes No <300 (10.4 nmol l−1)
‑or‑
Lab lower limit of normal
Yes Calculated method preferred
Lab lower limit of normal
EAU24 Yes No <349 (12.1 nmol l−1) Yes Calculated method preferred<63.5 (220 pmol l−1)
ICSM78 Yes No <230
230‑350 (gray zone)
>350 (no treatment)
Yes Calculated method preferred<65 (225 pmol l−1)
Joint society30 Yes No <230
230‑350 (gray zone)
>350 (no treatment)
Yes Equilibrium dialysis is gold standard
Lab lower limit of normal
23. 2010 U.S. Endocrine Society Guidelines: Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. Testosterone Therapy in Adult Men with Androgen Deficiency 
Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010 Jun;95(6):2536‑2559.
24. European Association of Urology (EAU): Dohle GR, Arver S, Bettocchi C, Kliesch S, Punab M, et al. Guidelines on male hypogonadism. Arnhem: European Association of Urology, 
2012 p2‑28. 
78. International Consultation on Sexual Medicine (ICSM): Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010 
Apr;7(4 Pt 2):1627‑1656. 
30. International Society of Andrology (ISA), International Society for the Study of the Aging Male (ISSAM), EAU, European Academy of Andrology (EAA) and Americal Society of 
Andrology (ASA) Joint Recommendations: Wang C, Nieschlag E, Swerdloff R, Hermann BM, Hellstrom WJ, et al. Investigation, Treatment, and Monitoring of Late‑Onset Hypogonadism 
in males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol. 2009;55:121‑30. 
EAU: European Association Of Urology; ICSM: International Consultation on Sexual Medicine; ISA: International Society of Andrology; EAA: European Academy of Andrology; ASA: 
American Society of Andrology; ISSAM: International Society for the Study of the Aging Male
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mood.23,24,30,78 Hypogonadal symptom screening questionnaires can 
be sensitive, but are poorly specific for diagnosing TD; accordingly, 
their use is not strongly recommended. Similarly, general population 
screening for TD is also discouraged.23,24,30,78
Physical exam is a helpful adjunct to symptom elucidation. Testicular 
volume < 10 ml is considered a strong predictor of TD, especially with 
increasing age. However, testicular volume must be interpreted in the 
context of existing co-morbidities and should prompt questioning as 
to historical risk factors for primary hypogonadism such as testicular 
trauma, chemotherapy, or prior surgery.77,82 Testes volumes < 5 ml in 
setting of elevated gonadotropins are highly suggestive of Klinefelter’s 
syndrome and warrant karyotype testing.77 Other helpful findings 
during the genital exam include assessment for a testicular asymmetry, 
varicoceles, or testicular masses. Additional general exam findings of 
gynecomastia, decreased body hair, visceral obesity, and diminished 
muscle mass are also helpful findings in the diagnosis of TD. Small, 
age-adjusted prostate volume has also been implicated as a diagnostic 
finding but is only corroborated by a few expert clinicians.77,78,82
Laboratory Diagnosis
Once patients are suspected of TD based upon clinical signs and 
symptoms, the diagnosis should be confirmed with laboratory testing 
to determine serum testosterone levels. Most agree this should be 
done initially by drawing a total serum testosterone level on two 
separate occasions during morning hours. As previously discussed, 
there is a diurnal variation in serum testosterone levels, and up to 
30% of patients with initially abnormal values have normal levels 
on repeat testing.19,20,83 Joint international society guidelines propose 
an upper limit of normal as 350  ng dl−1, above which treatment is 
usually not beneficial.30,78 However, the lower limit of normal, below 
which all appropriate individuals should undergo treatment, has not 
clearly been established. These same international society guidelines 
highlight population-based data from young men with TD undergoing 
TST that show the greatest benefit from treatment occurs in those 
with sexual symptoms and total serum testosterone levels < 230 ng 
dl−1.30,78 Other population-based data demonstrate variable threshold 
levels of total serum testosterone at presentation among different TD 
symptoms and individuals. Most symptoms correlate to a testosterone 
threshold level of 300 ng dl−1 at presentation, which corresponds to 
most laboratories’ lower limit of normal for young men.5,80,84 Based on 
this data, the 2006 U.S. Endocrine Society guidelines recommended a 
total serum testosterone level of 300 ng dl−1 as the diagnostic threshold 
for treatment. This is also the same value used by the United States 
Food and Drug Administration  (USFDA) to define hypogonadism 
for clinical trial purposes.22 However, in the 2010 Endocrine Society 
update, clinicians were instead referred to their individual laboratories 
reference ranges to guide treatment decisions due to several laboratory 
issues further adding to the difficulty in determining normal levels of 
serum testosterone.23,85
One laboratory issue is the preponderance of assays available 
including radioimmunoassay  (RIA), immunoassay  (IAs) and 
liquid chromatography-mass spectrometry  (LC-MS). RIA and IA 
are highly specific but can vary significantly between laboratories 
based upon antibody type used.22 LC-MS is accurate and precise but 
requires strict quality control and calibration. All three are plagued 
by decreased accuracy at testosterone levels below 300  ng dl−1. In 
addition, standardized laboratory specimen processing and equipment 
calibration standards do not yet exist.22
Regardless of which assay used, most authors agree that those 
patients who are clinically symptomatic with confirmed total serum 
testosterone levels < 230 ng dl−1 will benefit the most from treatment. 
In symptomatic men with confirmed levels  >  350  ng dl−1, several 
guidelines suggest that these patients may not experience benefit from 
treatment. However, some experts advocate for treatment in clearly 
symptomatic men regardless of serum testosterone levels, including 
those with levels > 350 ng dl−1.77 Within this group, experts attribute 
benefit of treatment to modulation of the androgen receptor, mediated 
by genetic polymorphisms in exon one of the androgen receptor gene 
in the form of increased cysteine adenosine guanine (CAG) repeats. 
Certain data have shown increased CAG repeats are associated with 
decreased sensitivity in the receptor to testosterone and manifestation 
of TD symptoms despite “normal” serum testosterone levels.86,87
Unfortunately, many patients who experience signs and symptoms 
of TD fall into the “gray area” of 230–350 ng dl−1. This may be due to 
altered serum SHBG levels as seen in older or obese patients, and SHBG 
levels should be checked and serum testosterone levels repeated. For 
these patients, total testosterone levels may not reflect bioavailable 
levels. In “gray area” patients, expert and guideline statements support 
the determination of biologically active testosterone by measuring 
free testosterone.23,30,77 Equilibrium dialysis is the gold standard for 
free testosterone measurement, but it is complex and not available at 
many laboratories.78 More commonly available analog assays are not 
recommended due to lack of sensitivity.13,88 Therefore, most laboratories 
utilize calculated free testosterone according to Vermeulen method, 
which is based upon serum total testosterone, SHBG and albumin 
levels. This has been shown to correlate well with equilibrium dialysis 
methods.13,89 Some experts, including these authors, advocate for use 
of calculated free testosterone levels in the diagnosis of all patients to 
avoid the ambiguity of total serum testosterone levels.77 If clinicians do 
not have free or bioavailable testosterone levels available at their local 
laboratory, they can check SHBG and albumin levels and then use an 
app such as “BioT” or online calculator (www.issam.ch/freetesto.htm) 
to calculate the levels of free and bioavailable testosterone.
Additional endocrine testing is warranted in those with suspected 
or confirmed TD. Serum LH levels should be measured to establish 
primary versus secondary hypogonadism. If LH levels are low and 
secondary hypogonadotropic hypogonadism is suspected, further 
testing is important to elucidate the underlying cause. These tests 
may include serum prolactin levels to rule out hyperprolactinemia, 
iron saturation studies to rule out the hemochromatosis, and estrogen 
levels to determine the testosterone to estrogen ratio.7,23,30,90 Some 
authors advocate for pituitary magnetic resonance imaging (MRI) if 
total serum testosterone levels are < 150 ng dl−1 coupled with either 
severely depressed gonadotropin levels or elevated prolactin levels are 
present.91 However, despite the dogma of pituitary MRI and the concern 
for a prolactinoma, the most common cause of hypogonadotropic 
hypogonadism with levels < 100 ng dl−1 is prior exposure to exogenous 
androgens.40 If primary hypegonadotropic hypogonadism is suspected, 
consideration should be made to perform karyotype testing for 
Klinefelter’s syndrome.23,92 TD also increases the risk for decreased bone 
mineral density and osteoporotic fracture.93 This effect is reversible 
in men of all ages on TST, with some experts recommending all 
osteoporotic men undergo TD evaluation.94,95,96 Therefore, baseline 
dual-energy X-ray absorptiometry  (DEXA) scanning should be 
considered in those with severe TD.23,30
TREATMENT
Treatment Goal
The goal of TST is to alleviate hypogonadal symptoms by restoring 
physiologic levels of serum testosterone. The exact serum testosterone 
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level required to achieve maximal efficacy and safety is currently 
unknown.30 Many authors often cite low-to-mid level range of 
serum testosterone levels as a reasonable target in otherwise young, 
asymptomatic men.86 These authors target a mid-to-high range, due to 
the lower risk of necessary dosing adjustments and a better chance for 
immediate symptom improvement resulting in improved compliance. 
However, there can be variation in what these ranges actually mean 
due to laboratory variation in assay type and processing, as well as 
individual variation due to CAG repeats mediating changes in androgen 
receptor sensitivity as previously discussed.78 Periodic observation 
of serum hormone concentration and its metabolites should be 
performed to minimize treatment-associated side-effects.97 Sustained 
supraphysiologic levels should be avoided.98 Improvement in symptoms 
should become apparent after 3 months of treatment. However, the 
results vary with the symptom. Energy and libido improve early, while 
osteoporosis may require as long as 1 year to improve.
Contraindications
There are certain clinical scenarios in which several specialty society and 
expert group guideline statements indicate caution or contraindication 
to TST.23,24,30,78 Breast cancer in men is rare and universally accepted as 
a clear contraindication.99,100 Presence of prostate cancer, particularly 
metastatic prostate cancer,101 has historically been considered a 
contraindication to TST. Several guideline statements still consider 
this to be a contraindication,20,24,30 including men at increased risk 
for developing prostate cancer-based upon the presence of a palpable 
nodule or elevated prostate specific antigen (PSA).102,103 Emergence of the 
saturation model104 has initiated a paradigm shift away from withholding 
TST in men with TD over concern for exogenous testosterone 
promoting development of prostate cancer.105 The 2010 Endocrine 
Society guidelines acknowledge that men at risk for prostate cancer may 
be treated with TST if cleared by a urologist after appropriate referral. 
A robust body of evidence supports this statement, but such men should 
still be closely monitored for development of prostate cancer while on 
TST.106–108 Furthermore, emerging data suggest TST in patients with a 
history of successfully treated, organ-confined prostate cancer is most 
likely safe.109–115 The most recent ICSM guidelines emphasize this point, 
stating that men with TD after successfully treated localized prostate 
cancer, without evidence of disease after a period of observation, are 
candidates for TST provided they have a thorough discussion of the 
potential risks and limited safety data.78
A similar paradigm shift has occurred for TST in men with 
benign prostate hyperplasia (BPH). The Endocrine Society guidelines 
recommend urology referral for TST in men with TD and significant 
lower urinary tract symptoms  (LUTS) based upon International 
Prostate Symptom Score (IPSS) >19. ICSM guidelines acknowledge 
demonstrated safety of TST in men with IPSS  >  21 based upon 
numerous studies, particularly after successful treatment of lower 
urinary tract obstruction.78,116 In addition, baseline hematocrit > 50%, 
uncontrolled or poorly controlled congestive heart failure, and 
obstructive sleep apnea are also contraindications.116 Finally, TST is 
clearly contraindicated in men with TD who still desire fertility and 
alternate therapies should be pursued.78
Preparations
Testosterone supplementation therapy exists as several different 
preparations administered by various routes, thereby requiring 
the treating physician to have an adequate understanding of the 
advantages and drawbacks of each preparation (Table 2). This is also 
important to facilitate the choice of agent by a shared physician-patient 
decision-making process.116 Due to the possibility of developing an 
adverse event during treatment requiring discontinuation, an initial 
trial of a short-acting agent that can be quickly withdrawn may be 
warranted, particularly in older patients.24,30
Although not available in the United States, oral agents are 
available internationally and provide TST in the convenience of a 
pill. Oral testosterone undecanoate is esterified to allow lymphatic 
absorption and partial avoidance of hepatic first-pass metabolism, 
but systemic absorption is still variable and at best serum levels 
reach mid-range.117,118 It is usually prescribed as a 2 or 3-dose 
regimen  (40–80  mg) when using capsules or tablets, respectively.97 
Oral 17-alpha-alkylated derivatives of testosterone can be more 
Table 2: Overview of available testosterone preparations









Apply daily. For dosing, 
see Table 3














Enanthate 200 mg ml−1 injection
Cypionate 100 or 200 mg ml−1 injection
150–200 mg q 2 weeks or 
75–100 mg IM q week








Aveed™ (undecanoate) 750 mg ml−1 750 mg IM q 4 week ×2, 
then q 10 weeks thereafter
Normal serum levels 



















Androderm® 2 and 4 mg patches 2‑6 mg (1–3 patches) q day Maintain physiologic 
levels for 24 h
Mimics circadian patterns
Ease of use
Skin irritation at 
application site
Nasal Natesto™ 5.5 mg 11 mg (2 pump actuations) 
TID
Peak serum levels within 





Lack of clinical data
IM: intramuscular; TID: three times daily; BID: twice daily
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effective, but have been associated with hepatotoxicity and are no 
longer used clinically.97,118 Buccal and sublingual formulations represent 
well-tolerated delivery systems with good efficacy due to avoidance of 
hepatic first-pass metabolism.24 Striant®, available as a 30 mg tablet, is 
the only buccal formulation available in the United States. The tablet 
should be applied every 12 h to the gum above the incisor tooth.117 
Absorption is rapid, reaching peak serum levels in 30 min, which is 
comparable to topical gel solutions.117,119 Commonly reported side 
effects generally occur in < 10% of patients and include a gum edema, 
gingivitis, gum blistering and bitter taste. Oral and buccal formulations 
are rarely used in the current management of TD due to better efficacy 
and lower side effects of newer formulations.
Intramuscular injections via an oil depot first became available 
in the 1950’s and are considered the most cost-effective form of TST. 
They are available in short and long-acting preparations. The shortest 
acting agent is testosterone propionate, which requires frequent doses 
and has led to infrequent usage due to the inconvenience.120 Slightly 
longer but still relatively short-acting agents testosterone enanthate 
and testosterone cypionate require injections every 1–2  weeks due 
to half-lives of 5–7 days, respectively. All of the short-acting agents 
are plagued by a “roller coaster” effect by achieving supraphysiologic 
levels within 2–4  days after injection followed by sub-therapeutic 
levels by 10–14 days.31,78,97,120 A rapid decline in serum levels around 
10–14 days has been called “testosterone crash” and is associated with 
sudden recurrence of TD symptoms.121 To minimize these effects, 
more frequent dosing from once to twice weekly has been suggested 
as is preferred by these authors. An additional drawback of injectable 
testosterone is an increased susceptibility of patients to develop 
erythrocytosis.122 Longer-acting injectable testosterone undecanoate 
(Aveed™) recently became USFDA-approved in 2014, with serum 
levels remaining in mid-normal range for up to 12 weeks after a single 
injection.
Subcutaneous testosterone pellets represent the longest-acting 
testosterone preparation, which have been available for decades but were 
approved as Testopel® by USFDA in 2008.123 The pellets are comprised 
of testosterone crystals and are inserted in a lateral hip or abdominal 
location, over time resulting in systemic absorption.124 Eight to fourteen, 
75 mg pellets are implanted into adipose tissue (600–1050 mg dose), 
dissolving in 3–4 months, with demonstrated physiologic levels for up to 
4 months.123,125,126 Traditionally, 5% of patients experience local side-effects 
including bleeding, infection, bruising, pain and pellet expulsion. More 
recent reports have described pellet extrusion rate to be < 1%.123
Transdermal testosterone preparations are currently the most 
commonly utilized forms of TST. Transdermal options include 
adhesive skin patches, topical gels, or topical solutions, all requiring 
daily or every other daily use to maintain serum levels within 
normal range.97 Transdermal preparations have a quick onset and a 
duration < 24–48 h allowing quick discontinuation should an adverse 
effect be experienced.127
Adhesive patches were initially developed for transcrotal application 
in the 1990’s (Testoderm) but were later discontinued due to significant 
skin irritation. More recently, nonscrotal patches (Androderm®) have 
been developed in 2 or 4  mg formulations, providing consistent 
testosterone delivery with kinetics mimicking normal circadian 
rhythms when applied nightly. Some earlier data have suggested better 
efficacy compared to intramuscular preparations, but patches are still 
plagued by local skin reactions including induration, vesicle formation, 
and contact dermatitis occurring in up to 37% of patients, leading to 
poor compliance.127,128 Use of a 0.1% triamcinolone corticosteroid 
cream at the patch site before patch application has been shown to 
diminish local skin reactions with minimal impact on testosterone 
delivery.129 Among transdermal preparations, patches have fallen out 
of favor due to the high rate of dermatitis.
Transdermal gels  (AndroGel 1%®, AndroGel 1.62%®, Testim®, 
Fortesta®, and Vogelxo™) and solutions (Axiron®) were first introduced 
in the United States in 2000 as an improvement over transdermal 
patches (Table 3). Dosing can be titrated individually based upon skin 
absorption rates related to metabolism across the stratum corneum.120 
The gels contain ethanol and are mixed with a skin permeation 
enhancer for application at same skin site daily on the shoulders, upper 
arms, abdomen or inner thigh during morning hours, with serum 
steady state levels achieved in 48–72  h.130 Application to multiple 
sites does not appear to effect overall systemic pharmacokinetics of 
transdermal gels.131 Axiron® is a topical alcohol-based testosterone (2%) 
solution applied in a similar way to axillary skin. In all cases, drying 
usually occurs within 10–15  min and hand washing is necessary 
to minimize contact spread to other individuals. This has led to 
recommendations for mandatory residence time at applications site 
of up to 2 h to minimize the transference.132 The risk of skin-to-skin 
contact has led to a USFDA black box warning on transdermal gel 
transference. Similar to patches, gels and solutions provide normal to 
elevated serum DHT levels due to dermal concentrations of 5-alpha 
reductase enzyme, which have been associated with hair loss. In 
general, transdermal gels are very well tolerated by patients with the 
















50 50–100 12.5 Upper arm, 
shoulder, 
abdomen
Wait 5 h Acne (5), gynecomastia (<3), 
headache (<3), hypertension (<3), 
prostate disorder (5)
Packet or pump available
AndroGel 
1.62%®
40.5 40.5–81 20.25 Upper arm, 
shoulder
Wait≥2 h PSA rise (11), emotional lability (2.5), 
hypertension (2), dermatitis (2)
Packet or pump available
Less volume per application
Fortesta® 40 10–70 10 Front and 
inner thighs
Wait≥2 h Skin reaction (16), PSA rise (1), 
abnormal dreams (1)




60 30–120 30 Both axilla Wait≥2 h Skin irritation (8), headache (6), 
diarrhea (4), vomiting (4), PSA rise (4)
Underarm application
Liquid consistency
Testim® 50 50–100 NA (1 tube=50 mg) Shoulder, 
upper arm
Wait≥2 h Skin reaction (4), hypertension (1), 
headache (1), bitter taste (1)
Unique scent
Travel friendly tube




Wait≥2 h Elevated hemglobin (2.8), applications 
site reaction (4)
Packet, pump or tube 
availability
Improved side effect profile
NA: not available; PSA: prostate specific antigen
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most commonly reported adverse reactions including acne, headache, 
emotional lability, nervousness, abnormal dreams, gynecomastia, 
and mastodynia, all occurring in < 8% of patients. Patients in whom 
the initial clinical response is unsatisfactory may try switching to an 
alternate gel or solution to improve serum testosterone levels.133
Recently approved by the USFDA on 5/28/2014, intranasal 
testosterone (Natesto™) represents another alternative route for TST. 
Recommended dosing is 11 mg 3 times daily, reaching maximum serum 
levels within 40 min with half-life ranging from 10–100 min.134,135 Phase 
three clinical trials demonstrated 90% effectiveness within 90 days of 
use with most commonly reported adverse reactions including PSA 
increase, headache, and local intranasal symptoms. Intranasal route 
minimizes close contact transference, but minimal data exist to date 
regarding overall tolerance and effectiveness outside of a clinical trial 
context.
The aromatase inhibitor anastrazole has demonstrated benefit 
in men with TD and infertility, and those with LOH, by improving 
serum androgen levels and testosterone/estradiol ratio.136–138 Due 
to its similarity to LH, human chorionic gonadotropin  (hCG) has 
been shown to improve the majority of TD symptoms in men with 
hypogonadotropic hypogonadism.139 In addition, concomitant 
administration of low dose hCG with TST has been shown to maintain 
spermatogenesis in hypogonadal men desiring fertility preservation 
while receiving TST.140 Clomiphene citrate, a selective estrogen receptor 
modulator, is not USFDA approved for TD but has demonstrated 
improvement in signs and symptoms, with a favorable safety profile 
and a protective effect on spermatogenesis, suggesting an important 
role in younger hypogonadal men wishing to preserve fertility.141–143 
Both clomiphene citrate and its isomer enclomiphene citrate, which 
is currently being tested in clinical trials, raise gonadotropins to 
improve hypogonadotropic hypogonadism. Through a positive LH 
effect endogenous testosterone production is increased, and a positive 
FSH effect may protect and potentially improve spermatogenesis.144,145 
Enclomiphene citrate in is phase 3 trials currently and is poised to 
be a very impactful treatment alternative to exogenous testosterone.
Monitoring
Several guideline statements agree23,24,30,78 all men diagnosed with TD 
wishing to undergo TST should be screened for contraindications as 
described above. All should have a baseline hematocrit, and those at 
potential risk for prostate cancer development should have a DRE 
and PSA screening regularly performed according to guideline 
recommendations.146 Those with LUTS associated with BPH should 
have symptoms evaluated and addressed at baseline, and those 
suspected of decreased bone mineral density should have a baseline 
DEXA scan.
Monitoring after initiation of treatment should occur more 
frequently initially, every 3–6  months for the first year and every 
6–12  months thereafter. At each visit, clinicians should specifically 
monitor for symptomatic improvement, treatment modality-specific 
adverse effects, serum total and free testosterone levels, serum 
hematocrit, and in those men identified at increased risk, DRE, PSA 
testing, and evaluation of LUTS should be performed. Most TD 
symptoms should be expected to improve by 3–6 months, but a few 
may require longer.147 PSA has been shown to have an initial rise after 
starting TST,148 on average rising 0.3 ng dl−1 in young men and 0.44 ng 
dl−1 in older men after 6 months of therapy, with a rise > 1.4 ng dl−1 being 
unusual.149 Subsequent rises in PSA may warrant discontinuation of 
therapy and prostate biopsy. Elevation in hematocrit is one of the most 
common adverse effects of TD and tends to occur more commonly 
in older men and with injectable preparations.116,150 It can take up to 
12 months for hematocrit levels to peak, but should they rise to > 54%, 
treatment should be attenuated and phlebotomy considered.147 Bone 
mineral density should be monitored every 1–2  years with repeat 
DEXA scan.
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